RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis

Journal of Musculoskeletal Neuronal Interactions

Volumn 4, Issue 3, 2004, Pages 276-284

  Ritchlin, C T ^a   Schwarz, Edward M ^a   O'Keefe, R J ^a   Looney, R J ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Aseptic loosening; Osteoclast precursors (OCP); Psoriatic arthritis(PsA); Rheumatoid arthritis (RA); Tumor necrosis factor alpha (TNF )

Indexed keywords

ADALIMUMAB; ALENDRONIC ACID; ANTIINFLAMMATORY AGENT; BISPHOSPHONIC ACID DERIVATIVE; CYTOKINE; CYTOKINE ANTIBODY; ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLACEBO; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ARTHRITIS; BONE DEVELOPMENT; BONE EROSION; BONE INJURY; BONE PROSTHESIS; CHONDROPROTECTION; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; IMPLANT; JOINT PROSTHESIS; METABOLIC BONE DISEASE; NONHUMAN; ORTHOPEDIC EQUIPMENT; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PROSTHESIS LOOSENING; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT PLANNING;

ANIMALS; ARTHRITIS; CARRIER PROTEINS; GLYCOPROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; OSTEOLYSIS; OSTEOPROTEGERIN; PROSTHESIS FAILURE; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 8644267545     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996; 85:307-310.
2. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423:356-361.
3. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19:163-196.
4. Feldmann M, Maini RN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003; 9:1245-1250.
5. Goldring SR, Gravallese EM. Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 2000; 12:195-199.
6. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
7. Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, Hieke K. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 2000; 39:122-132.
8. Van der Heijde D, Dankert T, Nieman F, Rau R, Boers M. Reliability and sensitivity to change of a simplification of the Sharp/Van der Heijde radiological assessment in rheumatoid arthritis. Rheumatology (Oxford) 1999; 38:941-947.
9. Weichselbaum A. Die feineren Veranderungen des Gelenkknorpels bei fungoser Synovitis und Karies der Gelenkenden. Archiv Pathol Anat Physiol Klin Med 1878; 73:461-475.
10. Bromley M, Woolley DE. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum 1984; 27:968-975.
11. Bromley M, Bertfield H, Evanson JM, Woolley DE. Bidirectional erosion of cartilage in the rheumatoid knee joint. Ann Rheum Dis 1985; 44:676-681.
12. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998; 152:943-951.
13. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000; 289:1504-1508.
14. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423:337-342.
15. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, Goldring SR. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000; 43:250-258.
16. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000; 43:259-269.
17. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999; 25:255-259.
18. Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, Woodring J, Pacifici R. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 2000; 106:1229-1237.
19. Kanematsu M, Sato T, Takai H, Watanabe K, Ikeda K , Yamada Y. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. J Bone Miner Res 2000; 15:1321-1329.
20. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 2001; 276:20659-20672.
21. Srivastava S, Toraldo G, Weitzmann MN, Cenci S, Ross FP, Pacifici R. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J Biol Chem 2001; 276:8836-8840.
22. Lubberts E, Joosten LA, Oppers B, Van Den Bersselaar L, Coenen-de Roo CJ, Kolls JK, Schwarzenberger P, Van de Loo FA, Van den Berg WB. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001; 167:1004-1013.
23. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999; 103:1345-1352.
24. Lubberts E, Joosten LA, Chabaud M, Van Den Bersselaar L, Oppers B, Coenen-De Roo CJ, Richards DC, Miossec P, Van Den Berg WB. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000; 105:1697-1710.
25. Mease PJ. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 2002; 61:298-304.
26. Gladman DD, Farewell VT, Nadeau C. Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol 1995; 22:675-679.
27. Resnick D, Niwayama G. Psoriatic arthritis. In: Resnick D (ed) Bone and Joint Imaging. WB Saunders, Philadelphia; 1989:320-329.
28. Fearon U, Griosios K, Fraser A, Reece R, Emery P, Jones PF, Veale DJ. Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 2003; 30:260-268.
29. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003; 111:821-831.
30. Yu X, Huang Y, Collin-Osdoby P, Osdoby P. Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res 2003; 18:1404-1418.
31. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402:304-309.
32. Pettit AR, Ji H, von Stechow D, Mueller R, Choi Y, Goldring SR, Benoist C, Gravallese EM. TRANCE/RANKL knockout mice are protected from bone erosion in the K/BxN serum transfer model of arthritis. Arthritis Rheum 2001; 44 (Suppl.):1638.
33. Romas E, Bakharevski O, Hards DK, Kartsogiannis V, Quinn JM, Ryan PF, Martin TJ, Gillespie MT. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum 2000; 43:821-826.
34. Romas E, Sims NA, Hards DK, Lindsay M, Quinn JW, Ryan PF, Dunstan CR, Martin TJ, Gillespie MT. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002; 161:1419-1427.
35. Lubberts E, Oppers-Walgreen B, Pettit AR, Van Den Bersselaar L, Joosten LA, Goldring SR, Gravallese EM, Van Den Berg WB. Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. Arthritis Rheum 2002; 46:3055-3064.
36. Schwarz EM. Unpublished data.
37. Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, Turk B, Pietschmann P, Woloszczuk W, Haralambous S, Kollias G, Striner G, Smoiolen JS, Schett G. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002; 46:785-792.
38. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002; 110:1419-1427.
39. Schett G, Redlich K, Hayer S, Zwerina J, Bolon B, Dunstan C, Gortz B, Shultz A, Bergmeister H, Kollias G, Steiner G, Smolen JS. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum 2003; 48:2042-2051.
40. Li P, Schwarz EM, O'Keefe RJ, Boyce BF, Xing L. RANK signaling independent and dependent stages of osteoclastogenesis in TNF-induced erosive arthritis. J Bone Miner Res 2003; 19:207-213.
41. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003; 48:3013-3022.
42. Li P, Schwarz EM, Li M, Looney RJ, Ritchlin CT, O'Keefe RJ, Boyce BF, Xing L. Systemic TNFα mediates an increase in peripheral CD11bhi osteoclast precursors in TNFα transgenic mice. Arthritis Rheum 2003; 50:265-276.
43. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93:165-176.
44. Komuro H, Olee T, Kuhn K, Quach J, Brinson DC, Shikhman A, Valbracht J, Creighton-Achermann L, Lotz M. The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. Arthritis Rheum 2001; 44:2768-2776.
45. Ralston SH, Hacking L, Willocks L, Bruce F, Pitkeathly DA. Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis 1989; 48:396-399.
46. Maccagno A, Di Giorgio E, Roldan EJ, Caballer LE, Perez Lloret A. Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis. Scand J Rheumatol 1994; 23:211-214.
47. Eggelmeijer F, Papapoulos SE, Van Paassen HC, Dijkmans BA, Valkema R, Westedt JL, Landman JO, Pauwels EK, Breedveld FC. Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum 1996; 39:396-402.
48. Valleala H, Laasonen L, Koivula MK, Mandelin J, Friman C, Risteli J, Konttinen YT. Two-year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. J Rheumatol 2003; 30:468-473.
49. Hasegawa J, Nagashima M, Yamamoto M, Nishijima T, Katsumata S, Yoshino S. Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. J Rheumatol 2003; 30:474-479.
50. Schwarz EM, Looney RJ, O'Keefe RJ. Anti-TNFα therapy as a clinical intervention for periprosthetic osteolysis. Arthritis Res 2000; 2:165-168.
51. Harris WH. The problem is osteolysis. Clin Orthop 1995(311):46-53.
52. Goldring SR, Jasty M, Roelke MS, Rourke CM, Bringhurst FR, Harris WH. Formation of a synovial-like membrane at the bone-cement interface. Its role in bone resorption and implant loosening after total hip replacement. Arthritis Rheum 1986; 29:836-842.
53. Margevicius KJ, Bauer TW, McMahon JT, Brown SA, Merrit K. Isolation and characterization of debris in membranes around total joint prostheses [see comments]. J Bone Joint Surg Am 1994; 76:1664-1675.
54. Horowitz SM, Doty SB, Lane JM, Burstein AH. Studies of the mechanism by which the mechanical failure of polymethylmethacrylate leads to bone resorption [see comments]. J Bone Joint Surg Am 1993; 75:802-813.
55. Jacobs JJ, Shanbjag A, Glant T, Black J, Galante JO. Wear debris in total joint replacements. J Am Acad Orthop Surg 1994; 2:212-220.
56. Goldring SR, Schiller AL, Roelke M, Rourke CM, O'Neil DA, Harris WH. The synovial-like membrane at the bone-cement interface in loose total hip replacements and its proposed role in bone lysis. J Bone Joint Surg Am 1983; 65:575-584.
57. Hirakawa K, Bauer TW, Stulberg BN, Wilde AH, Secic M. Characterization and comparison of wear debris from failed total hip implants of different types. J Bone Joint Surg Am 1996; 78:1235-1243.
58. Goodman SB, Chin RC, Chiou SS, Schurman DJ, Woolson ST, Masada MP. A clinical-pathologic-biochemical study of the membrane surrounding loosened and non-loosened total hip arthroplasties. Clin Orthop 1989; 182-187.
59. Jiranek WA, Machado M, Jasty M, Jevsevar D, Wolfe HJ, Goldring SR, Goldberg MJ, Harris WH. Production of cytokines around loosened cemented acetabular components. Analysis with immunohistochemical techniques and in situ hybridization [see comments]. J Bone Joint Surg Am 1993; 75:863-879.
60. Chiba J, Rubash HE, Kim KJ, Iwaki Y. The characterization of cytokines in the interface tissue obtained from failed cementless total hip arthroplasty with and without femoral osteolysis. Clin Orthop Rel Res 1994; (300):304-312.
61. Shanbhag AS, Jacobs JJ, Black J, Galante JO, Glant TT. Cellular mediators secreted by interfacial membranes obtained at revision total hip arthroplasty. J Arthroplasty 1995; 10:498-506.
62. Glant TT, Jacobs JJ. Response of three murine macrophage populations to particulate debris: bone resorption in organ cultures. J Orthop Res 1994; 12:720-731.
63. Nakashima Y, Sun DH, Trindade MC, Maloney WJ, Goodman SB, Schurman DJ, Smith RL. Signaling pathways for tumor necrosis factor-alpha and interleukin-6 expression in human macrophages exposed to titanium-alloy particulate debris in vitro [see comments]. J Bone Joint Surg Am 1999; 81:603-615.
64. Blaine TA, Rosier RN, Puzas JE, Looney RJ, Reynolds PR, Reynolds SD, O'Keefe RJ. Increased levels of tumor necrosis factor-alpha and interleukin-6 protein and messenger RNA in human peripheral blood monocytes due to titanium particles. J Bone Joint Surg Am 1996; 78:1181-1192.
65. Sabokbar A, Fujikawa Y, Neale S, Marray DW, Athanasou NA. Human arthroplasty derived macrophages differentiate into osteoclastic bone resorbing cells. Ann Rheum Dis 1997; 56:414-420.
66. Itonaga I, Sabokbar A, Murray DW, Athanasou NA. Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages. Ann Rheum Dis 2000; 59:26-31.
67. Sabokbar A, Kudo O, Athanasou NA. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. J Orthop Res 2003; 21:73-80.
68. Crotti TN, Smith MD, Findlay DM, Zreiqat H, Ahern MJ, Weedon H, Hatzinikolous G, Capone M, Holding C, Haynes DR. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. Biomaterials 2004; 25:565-573.
69. Gehrke T, Sers C, Morawietz L, Ffernahl G, Neidel J, Frommelt L, Krenn V. Receptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening. Scand J Rheumatol 2003; 32:287-294.
70. Sakai H, Jingushi S, Shuto T, Urabe K, Ikenoue T, Okazaki K, Kukita T, Jukita A, Iwamoto Y. Fibroblasts from the inner granulation tissue of the pseudocapsule in hips at revision arthroplasty induce osteoclast differentiation, as do stromal cells. Ann Rheum Dis 2002; 61:103-109.
71. Howie DW, Vernon-Roberts B, Oakeshott R, Manthey B. A rat model of resorption of bone at the cement-bone interface in the presence of polyethylene wear particles. J Bone Joint Surg Am 1988; 70:257-263.
72. Pap G, Machner A, Rinnert T, Horler D, Gay RE, Schwarzberg H, Neeumann W, Michel BA, Gay S, Pap T. Development and characteristics of a synovial-like interface membrane around cemented tibial hemi-arthroplasties in a novel rat model of aseptic prosthesis loosening. Arthritis Rheum 2001; 44:956-963.
73. Shanbhag AS, Hasselman CT, Rubash HE. The John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model. Clin Orthop 1997(344):33-43.
74. Merkel KD, Erdmann JM, McHugh KP, Abu-Amer Y, Ross FP, Teitelbaum SL. Tumor necrosis factor-alpha mediates orthopedic implant osteolysis. Am J Pathol 1999; 154:203-210.
75. Schwarz EM, Benz EB, Lu AL, Goater JJ, Mollano AV, Rosier RN, Puzas JE, O'Keefe RJ. A quantitative small animal surrogate to evaluate drug efficacy in preventing wear debris-induced osteolysis. J Orthop Res 2000; 18:849-855.
76. Kaar SG, Ragab AA, Kaye SJ, Kilic BA, Jinno T, Goldberg VM, Bi Y, Stewart MC, CArter JR, Greenfield EM. Rapid repair of titanium particle-induced osteolysis is dramatically reduced in aged mice J Orthop Res 2001; 19:171-178.
77. Wooley PH, Morren R, Andary J, Sud S, Yang SY, Mayton L, Markel D, Sieving A, Nasser S. Inflammatory responses to orthopaedic biomaterials in the murine air pouch. Biomaterials 2002; 23:517-526.
78. Schwarz EM, Lu AP, Goater JJ, Benz EB, Kollias G, Rosier RN, Puzas JE, O'Keefe RJ. Tumor necrosis factor-alpha/nuclear transcription factor-kappaB signaling in periprosthetic osteolysis. J Orthop Res 2000; 18:472-480.
79. Clohisy JC, Teitelbaum S, Chen S, Erdmann JM, Abu-Amer Y. Tumor necrosis factor-alpha mediates polymethylmethacrylate particle-induced NF-kappaB activation in osteoclast precursor cells. J Orthop Res 2002; 20:174-181.
80. Childs LM, Goater JJ, O'Keefe, Schwarz EM. Efficacy of Etanercept for Wear Debris-Induced Osteolysis. J Bone Miner Res 2001; 16:338-347.
81. Childs LM, Goater JJ, O'Keefe RJ, Schwarz EM. Effect of anti-tumor necrosis factor-alpha gene therapy on wear debris-induced osteolysis. J Bone Joint Surg Am 2001; 83-A:1789-1797.
82. Childs LM, Paschalis EP, Xing L, Dougall WC, Anderson D, Boskey AV, Puzas JE, Rosier RN, O'Keefe RJ, Boyce BF, Schwarz EM. In vivo RANK signaling blockade using the receptor activator of NF- kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res 2002; 17:192-199.
83. Goater JJ, O'Keefe RJ, Rosier RN, Puzas JE, Schwarz EM. Efficacy of ex vivo OPG gene therapy in preventing wear debris-induced osteolysis. J Orthop Res 2002; 20:169-173.
84. Ulrich-Vinther M, Carmody EE, Goater JJ, Soballe K, O'Keefe RJ, Schwarz EM. Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. J Bone Joint Surg Am 2002; 84-A:1405-1412.
85. Yang SY, Mayton L, Wu B, Goater JJ, Schwarz EM, Wooley PH. Adeno-associated virus-mediated osteoprotegerin gene transfer protects against particulate polyethylene-induced osteolysis in a murine model. Arthritis Rheum 2002; 46:2514-2523.
86. Looney RJ, Boyd A, Totterman S, Seo GS, Tamez-Pena J, Cambell D, Novotny L, Olcott C, Martell J, Hayes FA, O'Keefe RJ, Schwarz E. Volumetric computerized tomography as a measurement of periprosthetic acetabular osteolysis and its correlation with wear. Arthritis Res 2002; 4:59-63.
87. Schwarz EM, Campbell D, Totterman S, Boyd A, O'Keefe RJ, Looney RJ. Use of volumetric computerized tomography as a primary outcome measure to evaluate drug efficacy in the prevention of peri-prosthetic osteolysis: a 1-year clinical pilot of etanercept vs. placebo. J Orthop Res 2003; 21:1049-1055.